pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Brynovin
drug
save

sitagliptin

Marketedupdated 3mo ago
by Revio Therapeutics LLP
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval8 co-mentions · 4 sources
  • tagSmall Molecule4 co-mentions · 4 sources
  • drugSITAGLIPTIN AND METFORMIN HYDROCHLORIDE3 co-mentions · 1 sources
  • drugSITAGLIPTIN PHOSPHATE3 co-mentions · 3 sources
  • drugmetformin hydrochloride SR2 co-mentions · 1 sources
  • drugmetformin2 co-mentions · 1 sources
  • drugmetformin hydrochloride2 co-mentions · 1 sources
  • drugmetformin hydrochloride ER2 co-mentions · 1 sources

indications

investigational
Type 2 DiabetesDuchenne Muscular Dystrophy

all catalysts(0)

nothing on the calendar yet

Trials studying sitagliptin

  • phase1A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.active not recruitingn=12
  • phase4Semaglutide vs Sitagliptinenrolling by invitationn=58
  • phase4A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetesrecruitingn=204
  • N/AHbA1c Variability in Type II Diabetesactive not recruitingn=150
  • phase4Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)completedn=39
  • phase1A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteerscompletedn=60
  • phase2Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASHcompletedn=109
  • phase3A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetescompletedn=1,441
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Feb 25, 2035
~8.5 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (5)

  • Oct 23, 2040formulationUS 11944621
  • Oct 23, 2040formulationUS 12295953
  • Feb 25, 2035formulationUS 10925871
  • Feb 25, 2035formulationUS 10925871
  • Feb 25, 2035formulationUS 10925871

News(0)

no news has mentioned this drug yet

brand
Brynovin
generic
sitagliptin
indication
Duchenne Muscular Dystrophy
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?